Correlation of serum miR-892b with tumor markers and its clinical diagnostic efficacy in non-small cell lung cancer patients

Non-small cell lung cancer (NSCLC) poses a severe challenge to global public health safety. This research aimed at exploring the correlation between serum miR-892b and serum tumor marker (TMs) in NSCLC patients, and examining its significance in clinical diagnosis. For this research, 114 NSCLC patients and 108 healthy volunteers were enrolled. Quantitative reverse transcription PCR was employed to detect the expression of miR-892b in serum and tissues of NSCLC patients. The combined diagnostic value of miR-892b and TMs (carcinoembryonic antigen (CEA), cytokeratin 19 fragment 21-1 (CYFRA21-1), neuron-specific enolase (NSE) and carbohydrate antigen 125 (CA125)) in NSCLC was analyzed by receiver operating characteristic curve. The chi-square test was conducted to analyze the correlations between miR-892b and clinical data. Multivariate logistic regression analysis was conducted to pinpoint independent risk factors for NSCLC. MiR-892b was significantly elevated in the serum and tissues of NSCLC patients. Serum CEA, CYFRA21-1, NSE and CA125 levels were significantly higher than those of the control group. The combined diagnosis of miR-892b and TMs had higher diagnostic efficacy. High-expression miR-892b was strongly correlated with tumor-node-metastasis stage, tumor differentiation, lymph node metastasis stage, CEA, CYFRA21-1, NSE, and CA125. MiR-892b and TMs were identified as independent risk factors influencing NSCLC. MiR-892b may be a promising biomarker for NSCLC, which is important for enhancing the early diagnosis of NSCLC.